Skip to main content
European Commission logo
Enterprise Europe Network

A Korean company specialized in molecular diagnostic technology is looking for European partners who can develop all-in-one polymerase chain reaction(PCR) analyzer for home test

Summary

Profile Type
  • Technology request
POD Reference
TRKR20241030032
Term of Validity
31 October 2024 - 31 October 2025
Company's Country
  • South Korea
Type of partnership
  • Commercial agreement with technical assistance
  • Research and development cooperation agreement
Targeted Countries
  • All countries
Contact the EEN partner nearest to you for more information.
Find my local partner

General information

Short Summary
A Korean SME specialized in molecular diagnostic technology has been providing in vitro diagnostic test products. To meet growing demands for all-in-one PCR analyser for POCT (Point-of-Care Test), the company is seeking global partners who can mechanically design PCR analyzer for home test under commercial agreement with technical assistance or research cooperation agreement.
Full Description
A Korean SME, founded in 2013, is manufacturing in vitro diagnostic test products in the field of molecular, immunochemical and biochemical diagnostics. The company is supplying molecular diagnostic products to major hospital and research laboratories in Korea.

As the market demands more convenient and faster testing analyzers for Point-of-Care (POC) tests. The Korean company is developing an all-in-one PCR analyzer for home test that can provide the result within 60 minutes. Providing faster results leads to quicker intervention, enhances the screening processes and encourages regular testing.

The analyzer is expected to offer an automated pretreatment process using sonication, magnetic beads and smart valve. Those methods would optimize the pretreatment process and ensure the integrity of samples. Furthermore, the automation pretreatment process would not only minimize errors but also eliminate the need for specialized training, making it accessible to a broader range of users without limitations.

The PCR analyzer is expected to make a result including the pretreatment process under an hour by handling a variety of sample types such as blood, swabs, sputum, saliva and urine. The Korean company has a capability to develop reagents and algorithm to be applied to the all-in-one PCR analyzer.

The Korean company is looking for European partners who can develop all-in-one PCR analyzer for home test or provide mechanical design expertise under commercial agreement with technical assistance or research cooperation agreement. The technology must be patentable and the potential partner should have experience performing verification test for the technology.
Stage of Development
  • Concept stage
Sustainable Development Goals
  • Goal 3: Good Health and Well-being
IPR description
1) All-in-one PCR analyzer should make a result in 60 minutes including pretreatment and assay.
2) Specificity of the analyzer should be over 95%.
3) Limit of Detection (LOD) should be 5 copies/ ul
4) Potential partners should have experience in developing and commercializing all-in-one PCR analyzer for home test or Point Of Care Testing(POCT) system.

Partner Sought

Expected Role of a Partner
- Type of partner sought : Company, Institute, University

- Specific area of the partner : Health, Diagnostics, Medical device

- Specific activity of the partner : To mechanically design all-in-one PCR analyzer for home test under commercial agreement with technical assistance or research & development cooperation agreement
Type and Size of Partner
  • SME 11-49
  • University
  • SME <=10
  • R&D Institution
Type of partnership
  • Commercial agreement with technical assistance
  • Research and development cooperation agreement

Dissemination

Technology keywords
  • 06002007 - In vitro Testing, Trials
  • 06001005 - Diagnostics, Diagnosis
Market keywords
  • 05007007 - Other medical/health related (not elsewhere classified)
  • 04009 - In vitro Testing, Trials
  • 05001002 - In-vitro diagnostics
Sector Groups Involved
  • Health
Targeted countries
  • All countries